Department of Ophthalmology, Campus Kiel, University Medical Center Schleswig-Holstein UKSH, 24105 Kiel, Germany.
Int J Mol Sci. 2020 Dec 4;21(23):9272. doi: 10.3390/ijms21239272.
Age-related macular degeneration (AMD) is the major reason for blindness in the industrialized world with limited treatment options. Important pathogenic pathways in AMD include oxidative stress and vascular endothelial growth factor (VEGF) secretion. Due to their bioactivities, fucoidans have recently been suggested as potential therapeutics. This review gives an overview of the recent developments in this field. Recent studies have characterized several fucoidans from different species, with different molecular characteristics and different extraction methods, in regard to their ability to reduce oxidative stress and inhibit VEGF in AMD-relevant in vitro systems. As shown in these studies, fucoidans exhibit a species dependency in their bioactivity. Additionally, molecular properties such as molecular weight and fucose content are important issues. Fucoidans from and were identified as the most promising candidates for further development. Further research is warranted to establish fucoidans as potential therapeutics for AMD.
年龄相关性黄斑变性（AMD）是工业化世界致盲的主要原因，其治疗选择有限。AMD 的重要发病途径包括氧化应激和血管内皮生长因子（VEGF）分泌。由于其生物活性，褐藻胶聚糖最近被提议作为一种潜在的治疗方法。本文综述了该领域的最新进展。最近的研究已经从不同物种中对几种褐藻胶聚糖进行了描述，这些褐藻胶聚糖具有不同的分子特征和不同的提取方法，在降低 AMD 相关体外系统中的氧化应激和抑制 VEGF 方面具有不同的能力。如这些研究所示，褐藻胶聚糖在其生物活性方面表现出种属依赖性。此外，分子量和岩藻糖含量等分子特性也是重要问题。和 中的褐藻胶聚糖被确定为进一步开发的最有前途的候选物。有必要进行进一步的研究，以确立褐藻胶聚糖作为 AMD 的潜在治疗方法。
Zotero 插件